A randomized, double-blind, placebo-controlled 16 week study of the H3 receptor antagonist GSK239512 in subjects with mild-to-moderate Alzheimer's disease (AD)

Saved in:
Bibliographic Details
Published inAlzheimer's & dementia Vol. 7; no. 4; pp. e58 - e59
Main Authors Grove, Richard, Horrigan, Joseph, Harrington, Conn, Beresford, Isabel, Mahler, Andreas
Format Journal Article
LanguageEnglish
Published Elsevier Inc 01.07.2011
Subjects
Neurology
Online AccessGet full text

Cover

Be the first to leave a comment!
You must be logged in first